Amazing news to see the appointment of a Head of Business Development – especially considering the trust in the FDA process and the strong regulatory focus. That part seems solid and adds a good level of credibility.
However, I’m not as enthusiastic about Nick’s appointment as many others here seem to be. Leaving Rcare shortly after being promoted to CEO – just 8 months in – doesn’t exactly inspire confidence. Combined with Nick’s track record (taking 6 years to complete an MBA and holding several roles for only a bit over a year), it doesn’t give the impression of long-term commitment or stability to me.I was hoping for someone with a more consistent background and a clearer indication of long-term leadership. So yes, a bit disappointed with this choice – even though the broader outlook still seems promising for now.
PCK Price at posting:
4.6¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)